Products for Research Use Only
RegisterLogin

Navepdekinra

CAT: 0804-HY-153780-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153780-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM) . Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis[1][2][3].
CAS Number
2467732-66-5
Product Name Alternative
DC-806; LY4100504; S-011806
UNSPSC
12352005
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/navepdekinra.html
Purity
98.58
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=NN1CC)N[C@@H]([C@@]2([H])CC[C@@H](CC2)C)C(NC3=C(C=C(C=C3)[C@H](C)[C@@H](NC(CC)=O)C(N4CCN(CC4)C)=O)F)=O
Molecular Formula
C33H48FN7O4
Molecular Weight
625.78
References & Citations
[1]Paul R. Fatheree, et al. IL-17 Ligands And Uses Thereof. US20200247785A1.|[2]Kim D, et al. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. Am J Clin Dermatol. 2025 May;26 (3) :307-320.|[3]Xiaobing Deng, et al. The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors. bioRxiv 2025.10.02.680113
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-17

Alternative Products

CatalogName
GTR19239891-01Navepdekinra

Popular Products